Liraglutide · source year
4 selected, source-linked Liraglutide records carrying a 2019 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
1 represented type.
4 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02488057 at 2026-07-30T20:47:16.573Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01179048 at 2026-07-30T20:48:52.462Z. Its registry update date was 2019-07-17, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02060383 at 2026-07-30T20:52:10.194Z. Its registry update date was 2019-05-29, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02911818 at 2026-07-30T20:52:10.188Z. Its registry update date was 2019-05-07, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗